This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ventas (VTR) Concludes New Senior Investment Group Acquisition
by Zacks Equity Research
Ventas' (VTR) latest acquisition of New Senior Investment positions the healthcare REIT well to bank on the senior housing industry's recovery.
Ventas (VTR) Inches Closer to New Senior Investment Merger
by Zacks Equity Research
Ventas (VTR) moves closer toward its proposed merger of New Senior Investment Group with an approval of the latter's stockholders.
Here's Why You Should Hold Ventas (VTR) Stock in Your Portfolio
by Zacks Equity Research
While Ventas' (VTR) office segment and senior housing operations have upside potential, competition from national and local healthcare operators is a concern.
Ventas (VTR) Q2 FFO Tops Estimates, Senior Housing Occupancy Up
by Zacks Equity Research
Ventas' (VTR) Q2 results reflect sequential occupancy improvement in its Senior Housing Operating Portfolio segment as well as growth in the Office segment.
Ventas (VTR) Q2 FFO Beat Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 1.39% and -0.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Ventas (VTR) This Earnings Season?
by Zacks Equity Research
While Ventas (VTR) is well poised to bank on the senior housing industry's recovery that is likely to have aided it in Q2, disposition of assets and higher expenses might have been deterrents.
Chimera (CIM) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
While securitizations in the prior quarters are likely to have provided stable interest income for Chimera (CIM) in Q2, a challenging backdrop for Agency securities is likely to have hurt valuations.
Healthpeak (PEAK) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
While life-science and medical office portfolios are likely to have aided Healthpeak (PEAK) in Q2, large asset disposals and lower occupancy levels at senior housing facilities are the headwinds.
Ventas (VTR) to Acquire New Senior Investment in $2.3B Deal
by Zacks Equity Research
Ventas' (VTR) deal to acquire New Senior Investment will poise the healthcare REIT well to capitalize on the senior housing industry's recovery and will likely be accretive to its FFO per share.
Ventas (VTR) Q1 FFO Beats, Senior Housing Occupancy Dips
by Zacks Equity Research
While Ventas' (VTR) office portfolio displays marginal net operating income growth, declining occupancy at its senior housing operating portfolio continues to be a deterrent in Q1.
Ventas (VTR) Tops Q1 FFO and Revenue Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 2.86% and 1.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Lamar (LAMR) Beats Q1 Revenue Estimates, Raises 2021 View
by Zacks Equity Research
Lamar's (LAMR) Q1 results reflect higher-than-anticipated revenues. The REIT also raised its prior guidance for 2021 on anticipated continued recovery from the pandemic.
Ventas (VTR) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
While the gradual rebound in clinical activity is expected to have supported Ventas' (VTR) office segment performance, the pandemic-led concerns continued to be setbacks for its seniors housing business.
Will Central Banks Start to Care About Fundamentals?
by John Blank
Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.
Is Recovery in the Cards for Welltower (WELL) in Q1 Earnings?
by Zacks Equity Research
Despite increased coverage of vaccine administration among senior housing residents, Welltower (WELL) witnesses a significant occupancy decline at its senior housing operating portfolio in Q1.
Life-Science Assets to Aid Ventas (VTR) Amid Pandemic Woes
by Zacks Equity Research
Amid the COVID-19 outbreak, which is taking a toll on Ventas' (VTR) senior housing operations, the company is attuning its portfolio with higher exposure to resilient office segment assets.
Welltower (WELL) Expects 1Q21 FFO to Reach Top-End of Outlook
by Zacks Equity Research
Backed by a rise in vaccination coverage, the removal of admission bans and a spike in move-ins, Welltower's (WELL) seniors housing occupancy decline moderated in March. This will aid Q1 results.
Ventas (VTR) Up 5.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ventas (VTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mack-Cali (CLI) Q4 FFO & Revenues Miss Estimates, NOI Declines
by Zacks Equity Research
Mack-Cali's (CLI) fourth-quarter results were hindered by the same-store cash revenue and net operating income declines in its office portfolio.
American Tower (AMT) Q4 AFFO Lags Estimates, '21 View Strong
by Zacks Equity Research
Despite a decline in revenues in the Asia Pacific and Latin America property segments, American Tower (AMT) sees strong organic tenant billing growth in Q4.
Iron Mountain (IRM) Beats on Q4 FFO, Eyes Expansion in India
by Zacks Equity Research
Despite organic growth in core storage business, Iron Mountain's (IRM) Q4 performance is affected by service revenue declines. The company enters into a joint venture for data-center expansion in India.
SBA Communications (SBAC) Tops on Q4 AFFO, Hikes Dividend
by Zacks Equity Research
SBA Communications' (SBAC) strong Q4 results reflect strength in its domestic site-leasing business. It signs a long-term lease to rent out its towers to DISH and hikes dividends by 25%.
Ventas (VTR) Q4 FFO Tops Estimates, Revenues & NOI Decline Y/Y
by Zacks Equity Research
Decent performance of office portfolio aides Ventas (VTR) Q4 results. However, pandemic-led seniors housing woes continue to mar the senior housing operating portfolio performance.
Ventas (VTR) Q4 FFO Surpass Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 13.70% and -0.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
REITs' Q4 Earnings Lined Up for Feb 18: VTR, VICI & More
by Moumita C. Chattopadhyay
Since the economic disruption and its impact have been widely varied across different property types, delving deeper into each REIT's asset fundamentals and markets is now all the more important.